ESMO 2021 Prostate Cancer - Results from #40

Viewing 41-60 of 74 articles

ESMO 2021: Pembrolizumab Monotherapy for Docetaxel-Pretreated mCRPC: Updated Analyses with 4 Years of Follow-up from Cohorts 1-3 of the KEYNOTE-199 Study

ESMO 2021: Time Course Profile of Adverse Events of Interest and Serious Adverse Events with Darolutamide in the ARAMIS Trial

ESMO 2021: TALAPRO-3: A Phase 3, Double-blind, Randomized Study of Enzalutamide Plus Talazoparib versus Placebo Plus Enzalutamide in Patients with DDR Gene Mutated Metastatic Castration-sensitive Prostate Cancer

ESMO 2021: Patient-Reported Outcomes in Prostate Cancer Patients Receiving PSMA-Targeted Radionuclide Therapy

ESMO 2021: Systemic Treatments and Novel Approaches

ESMO 2021: Treatment Patterns and Overall Survival in Metastatic Castration-Sensitive Prostate Cancer from 2006 to 2019

ESMO 2021: Apalutamide Efficacy and Safety in Asian Patients with Metastatic Castration-Sensitive Prostate Cancer

ESMO 2021: Artificial Intelligence To Guide Prostate Cancer Therapeutic Strategies

ESMO 2021: Analysis of Serial PET Imaging and Paired Tc99 Scans in Metastatic Castration Resistant Prostate Cancer (mCRPC) Treated with Enzalutamide,

ESMO 2021: Health-Related Quality of Life (HRQoL) in ACIS: a Phase 3 Trial of Apalutamide With Abiraterone Acetate and Prednisone (APA + AAP) vs AAP in Metastatic Castration-Resistant Prostate Cancer (mCRPC),

ESMO 2021: The Role of Radiotherapy

ESMO 2021: Pain Efficacy With Radium-223 in Patients With Metastatic Castration-Resistant Prostate Cancer in the PARABO Observational Study

ESMO 2021: PRIMORDIUM – A Randomized, International, Trial-in-Progress of Adding Apalutamide to Radiotherapy and an LHRH Agonist in High-Risk Patients With PSMA-PET-Positive Hormone-Sensitive Prostate Cancer

ESMO 2021: Molecular Pathology to Advance Prostate Cancer Precision Medicine

ESMO 2021: Phase 2 Neoadjuvant Trial of the anti–B7-H3 Antibody, Enoblituzumab, in Men with Localized Prostate Cancer: Safety, Efficacy, and Immune Correlates

ESMO 2021: MGC018, an anti-B7-H3 Antibody-drug Conjugate (ADC), in Patients with Advanced Solid Tumors: Preliminary Results of Phase 1 Cohort Expansion

ESMO 2021: Clinical Perspectives for the Individual Patient and the Community

ESMO 2021: Efficacy and Safety of Relugolix vs Leuprolide in Men with Advanced Prostate Cancer: Clinical Subgroup Analysis from the Phase 3 HERO Study

ESMO 2021: Geographical Assessment of Efficacy and Safety of Relugolix: A Subgroup Analysis from the Randomized, Phase 3 HERO Study vs Leuprolide in Men with Advanced Prostate Cancer

ESMO 2021: Role of Serum Biomarkers of Bone Metabolism in mCRPC Patients Treated with Radium-223: PRORADIUM Study Final Results

1
2
3
4